Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Immuneering Corporation Class A Common Stock

IMRX

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.

Last trade $3.35
Day change -$0.17 (-4.83%)
Day range $3.32 – $3.68
Volume 682,463
Market cap $228M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$227.97M
Price / earnings
—
Price / book
1.35×
Price / sales
—
EV / sales
—
EV / EBITDA
-2.31×

Profitability

Earnings per share
-$1.03
Return on assets
-36.43%
Return on equity
-39.43%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
13.97×
Quick ratio
13.97×
Cash ratio
5.4×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$61.81M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for IMRX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$5.06M$5M$4.68M$4.49M$4.51M$4.3M$4.01M$3.69M
Research and development$20.72M$14M$10.65M$9.25M$10.87M$10.45M$11.47M$14.86M
Total operating expenses$25.79M$19M$15.34M$13.75M$15.38M$14.76M$15.48M$18.56M
Operating income-$25.79M-$19M-$15.34M-$13.75M-$15.38M-$14.76M-$15.48M-$18.56M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$24.19M-$17.27M-$13.46M-$11.58M-$14.96M-$14.43M-$15.05M-$18.05M
Income taxes$0$0$0$0$0$0$0$0
Net income-$24.19M-$17.27M-$13.46M-$11.58M-$14.96M-$14.43M-$15.05M-$18.05M
Net income attributable to common shareholders-$24.19M-$17.27M-$13.46M-$11.58M-$14.96M-$14.43M-$15.05M-$18.05M
EBITDA-$25.69M-$18.91M-$15.25M-$13.67M-$15.29M-$14.67M-$15.39M-$18.46M
Basic earnings per share-$0.37-$0.27-$0.21-$0.18-$0.38-$0.40-$0.42-$0.58
Diluted earnings per share-$0.37-$0.27-$0.21-$0.18-$0.38-$0.40-$0.42-$0.58

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Immuneering Corporation announced preclinical data demonstrating that atebimetinib, a MEK inhibitor, enhances PD-1 checkpoint blockade in RAS mutant tumor models. The findings support the company's plans to conduct a Phase 2 study combining atebimetinib with PD-1 blockade in lung cancer patients. The poster will be presented at the SITC 41st Annual Meeting in November 2026.

GlobeNewswire Inc.

Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients

Following an FDA approval of a second-line pancreatic cancer treatment, Immuneering Corporation reaffirmed its focus on first-line metastatic pancreatic cancer patients. The company is enrolling patients in its Phase 3 MAPKeeper 301 trial evaluating atebimetinib combined with chemotherapy. Previous Phase 2a data showed 17.3-month median overall survival with manageable side effects, with 84% of patients maintaining or gaining weight at three months.

Benzinga

Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Drop— AZZ, Northrop Grumman, Immuneering In Focus (UPDATED)

U.S. stock futures declined on Thursday with investors awaiting Supreme Court ruling on tariffs and December jobs reports. AZZ surged on strong earnings, Northrop Grumman jumped on defense spending proposals, while Immuneering tumbled on disappointing trial data and Phathom dropped following stock offering announcement. Constellation Brands rose on better-than-expected earnings.

GlobeNewswire Inc.

Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Immuneering Corporation announced positive Phase 2a trial results showing 64% overall survival at 12 months for atebimetinib combined with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients, nearly double the 35% benchmark from standard of care. The company plans to initiate its pivotal Phase 3 trial (MAPKeeper 301) in mid-2026, with FDA and EMA alignment already secured on trial design.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.